Quantinno Capital Management LP Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Quantinno Capital Management LP boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 82.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,059 shares of the medical research company's stock after purchasing an additional 8,138 shares during the quarter. Quantinno Capital Management LP's holdings in IQVIA were worth $4,280,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. PGGM Investments lifted its position in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after buying an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Raymond James & Associates grew its stake in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Versor Investments LP purchased a new stake in shares of IQVIA during the 3rd quarter valued at $1,328,000. Finally, Gradient Investments LLC raised its stake in shares of IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock worth $9,600,000 after purchasing an additional 6,134 shares during the period. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a report on Friday, November 1st. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Morgan Stanley decreased their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Finally, Robert W. Baird cut their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $256.50.

IQVIA Price Performance

Shares of NYSE IQV traded up $3.81 during mid-day trading on Monday, reaching $206.44. 1,748,849 shares of the company were exchanged, compared to its average volume of 1,182,642. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company's 50 day moving average price is $215.18 and its 200 day moving average price is $225.10. The stock has a market capitalization of $37.47 billion, a PE ratio of 26.59, a PEG ratio of 2.08 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.